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Abstract
Background: Despite many initiatives to enhance the rational use of antibiotics, there remains substantial room for
improvement. The overall aim of this study is to optimise the appropriate use of antibiotics in German ambulatory
care in patients with acute non-complicated infections (respiratory tract infections, such as bronchitis, sinusitis,
tonsillitis and otitis media), community-acquired pneumonia and non-complicated cystitis, in order to counter the
advancing antimicrobial resistance development.
Methods: A three-armed cluster randomised trial will be conducted in 14 practice networks in two German federal
states (Bavaria and North Rhine-Westphalia) and an added cohort that reflects standard care. The trial is accompanied
by a process evaluation.
Each arm will receive a different set of implementation strategies. Arm A receives a standard set, comprising
of e-learning on communication with patients and quality circles with data-based feedback for physicians,
information campaigns for the public, patient information material and performance-based additional reimbursement.
Arm B receives this standard set plus e-learning on communication with patients and quality circles with data-based
feedback tailored for non-physician health professionals of the practice team and information material for tablet
computers (culture sensitive). Arm C receives the standard set as well as a computerised decision support system and
quality circles in local multidisciplinary groups.
The study aims to recruit 193 practices which will provide data on 23,934 patients each year (47,867 patients in total).
The outcome evaluation is based on claims data and refers to established indicators of the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net). Primary and secondary outcomes relate to prescribing of antibiotics,
which will be analysed in multivariate regression models. The process evaluation is based on interviews with surveys
among physicians, non-physician health professionals of the practice team and stakeholders. A patient survey
is conducted in one of the study arms. Interview data will be qualitatively analysed using thematic framework
analysis. Survey data of physicians, non-physician health professionals of the practice team and patients will
use descriptive and exploratory statistics for analysis.
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Discussion: The ARena trial will examine the effectiveness of large scale implementation strategies and explore their
delivery in routine practice.
Trial registration: ISRCTN, ISRCTN58150046. Registered 24 August 2017.
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Background
Antimicrobial resistance remains high on the health
agenda. In Germany, a national policy agenda has rein-
forced policies to restrain antibiotic prescribing in medi-
cine [1]. Despite decades of scientific research on
rational use of antibiotics, and subsequent development
of evidence-based practice guidelines [2], there remains
a substantial room for improvement. For instance, data
on patients with lower respiratory tract infections in
German general practice showed that antibiotics were
prescribed in 41% of consultations, of which 52% were
congruent with guideline recommendations [3]. Strategies
to optimise antibiotic prescribing can be effective. A clus-
ter randomised trial in 259 practices in six European
countries found that continuing education for physicians
reduced their antibiotic prescribing by about 50% (from
about 80 to 40%) in patients with respiratory tract
infections [4]. However, it is unclear whether these
impacts can also be achieved in large scale programs.
The focus in the study described here is on scaling up
existing implementation strategies to achieve sustainable
and large-scale uptake of recommended use of antibiotics
in ambulatory care in Germany.
In order to address a wide range of barriers for
implementation, the increased rational use of antibi-
otics requires a complex implementation strategy––an
intervention with multiple components interacting
with each other. Based on relevant published research,
which was identified through a literature review, and ex-
perience in quality improvement programs [5, 6], compre-
hensive implementation programs were developed in
close collaboration with participating practice networks as
key stakeholders. These programs address physician
knowledge and attitudes about the use of antibiotics as
well as the ambulatory care team, patient experiences and
reimbursement. In the planned study, the effectiveness of
these implementation programs will be examined.
A process evaluation will be conducted to understand
the mechanisms underlying the effectiveness and to en-
sure generalizability of intervention effectiveness [7, 8].
Therefore, the process evaluation will explore which
components of the programs and which contextual fac-
tors contribute to the effects. This knowledge is essential
for building an evidence base that informs policy and
practice [9]. The process evaluation will focus on the
role of networks of ambulatory practices in Germany
(‘Arztnetze/Praxisnetze’), in which the ARena project is
embedded. These practice networks organise quality im-
provement and additional reimbursement for specific ac-
tivities for participating ambulatory practices. Exploring
the impact of those networks on antibiotic prescribing is
of particular interest. The networks may enhance the
contagion of new ideas and practices through various
mechanisms of social influence between participating
healthcare providers and thus enhance the contagion of
knowledge and practices [10]. Reducing antimicrobial re-
sistance is only possible if the large majority of physi-
cians join efforts to reduce antibiotic prescribing. The
context of a sustained network may influence physicians’
willingness to cooperate with programs such as ARena
because the repeated interaction in the network
enhances mutual trust and facilitates the exclusion of
non-cooperators [11].
The planned study has three central aims: (a) to deter-
mine and compare the effectiveness of three implemen-
tation programs to optimise antibiotic prescribing in
ambulatory care, (b) to compare the outcomes of the
three implementation programs with standard care and
(c) to provide insight into the fidelity of the implementa-
tion programs, their potential working mechanisms and
the impact of health system-related factors on outcomes.
Methods/design
Study design
This three-armed (non-blinded) cluster randomised trial
consists of different components which aim to achieve
sustainable and large-scale uptake of recommended use
of antibiotics in ambulatory care in Germany. Each of
the three arms will receive a different set of components.
The components are based on published research and
experiences in improvement programs. Figure 1 presents
the study design.
The study is planned for 30 months, with an intervention
period of 24 months, and split into two parts of evaluation:
(a) an outcome evaluation based on claims data and (b) a
process evaluation. The process evaluation will focus on
physicians allocated to one of the three intervention arms,
non-physician health professionals of the practice team in
intervention arm B, as well as stakeholders (see Fig. 2). In
Germany, beside physicians, only one non-physician health
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professional (‘Medizinische Fachangestellte’) is involved in
ambulatory care. This role is comparable to medical assis-
tants in the USA [12]. Additionally, a patient survey will be
conducted in intervention arm B.
The ARena study is approved by the ethics committee
of the Medical Faculty of the University of Heidelberg
(reference number S-353/2017).
Implementation strategies
The implementation strategies will be gradually applied
during the intervention period of the study. Intervention
group A receives a conventional improvement program
with five components targeting physicians and patients.
Intervention group B receives the conventional program
as well as additional components, which target medical as-
sistants and patients. Intervention group C receives the
conventional program and a different set of additional
components which target physicians as well as other
healthcare providers, like pharmacist and representatives
of hospitals or nursing homes. In total, the implementa-
tion programs consist of 10 intervention components
(Table 1) and take the concept of blended learning into
consideration. The specific components are briefly de-
scribed in this section and characterised in more details
according to the TIDieR checklist [13] in Additional file 1.
Intervention group A (multifaceted intervention
program for physicians and patients):
1) E-learning on communication with patients for
physicians: Patient-centred communication skills are
trained, using videotaped consultations, checklists for
use in consultations and patient education material.
The focus is on exploration of patient expectations,
delayed prescription, if necessary, and shared decision
making.
2) Quality circles with data-based feedback for physicians:
Four moderated meetings of physicians spread over a
period of 2 years, using practice-specific feedback on
prescriptions as well as evidence-based information on
antimicrobial resistance and prescribing of antibiotics
as input.
3) Information campaigns for the public: The
information campaign includes social media
(Facebook, Twitter, YouTube), explanatory videos,
expert interviews, radio and print material. Patient
information is provided online (arena-info.org;
arena-info.de), using lay language and a
user-responsive design. Local healthcare providers are
involved, as far as possible. Patient leaflets, which can
be individualised to practices, are available in various
Fig. 1 ARena study design with three intervention arms and comparison group
Fig. 2 Process evaluation design of the ARena study
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languages. The information for the public relates to
relevant other campaigns on antimicrobial resistance
and use of antibiotics, such as the European antibiotics
day (18th November––every year).
4) Patient information material: Posters and leaflets
are provided to deliver information on antibiotic
prescribing to patients with acute non-complicated
infections, mainly using existing material from
established organisations.
5) Performance-based additional reimbursement:
Practices with relatively high numbers of patients
with acute respiratory symptoms, bronchitis,
tonsillitis, sinusitis or otitis media without
antibiotic prescription receive additional
reimbursement. The algorithm for the
performance-based payment, which will be
developed, considers the empirical distribution
among practices and the available budget.
Intervention group B (multifaceted intervention
program for non-physician health professionals of the
practice team and patients):
Components 1–5 plus:
6) E-learning on communication with patients for
medical assistants: Medical assistants (‘Medizinische
Fachangestellte’) receive training, which is focused
on communication with patients and practice
organisation.
7) Quality circles with data-based feedback for
medical assistants: Four moderated meetings of
medical assistants spread over a period of 2 years,
using practice-specific feedback on prescriptions and
patient surveys.
8) Information material for tablet computers: A tablet
computer (culture sensitive tailoring: English, Turkish,
Russian, Arabic) is provided to deliver information on
antibiotic prescribing to patients with acute
non-complicated infections, mainly using existing
material from established organisations.
Intervention group C (multifaceted intervention
program for physicians with additional strategies):
Components 1–5 plus:
9) Computerised decision support system (CDSS): A
CDSS is installed in the practice information system.
After coding of a relevant diagnosis or antibiotics in
the practice system, the CDSS generates a pop-up
with a recommendation on prescription of
antibiotics based on evidence-based clinical
guidelines. The tool is provided by different software
providers.
10) Quality circles in multidisciplinary groups:
Representatives of local healthcare providers (such
as ambulatory physicians, hospitals, nursing homes,
home nursing, pharmacists) are invited to
multidisciplinary, cross-sectoral quality circles. The
emphasis of the meetings is on providing information
and education on antimicrobial resistance and
antibiotic prescribing and to coordinate a regional
joint course of action for the rational use of
antibiotics.
Study population
Fourteen practice networks in two German federal states
(Bavaria and North Rhine-Westphalia) are recruited for
participation in the ARena project. For administrative
reasons, the study will focus on patients insured by
AOK health insurance, which are registered within a
specific program for healthcare delivery (‘Besondere
Versorgung’ as defined by German law § 140a SGB V
a.F. bzw. § 140a Abs. 1. S. 2 Alt. 1 SGB V n.F). Compared
to patients insured by other German health insurances,
AOK-insured patients have somewhat lower income, less
education, higher probability of migration background
and lower self-reported health status [14]. On average,
35% of the population within the geographic reach of the
participating practice networks in Bavaria are insured by
AOK health insurance. At baseline, approximately 40,000
patients with AOK health insurance are registered in 193
participating ambulatory care practices in these 14 net-
works. In total, there are 304 eligible ambulatory care
practices in these 14 networks. The patient population for
the intervention arms will comprise patients who attended
ambulatory practices for the following reasons: acute non-
complicated infections of the respiratory tract (bronchitis,
sinusitis, tonsillitis, otitis media), non-complicated cystitis
Table 1 Overview of intervention components
Intervention
arm
Intervention components A B C
1) E-learning for physicians x x x
2) Quality circles with data-based feedback
for physicians
x x x
3) Information campaigns for the public x x x
4) Information campaigns for patients in
respective practices
x x x
5) Performance-based additional reimbursement
(P4P)
x x x
6) E-learning for medical assistants x
7) Quality circles with data-based feedback for
medical assistants
x
8) Information material available on tablet computers x
9) Computerised decision support system (CDSS) x
10) Quality circles in local multidisciplinary groups x
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and community-acquired pneumonia (CAP). The
diagnoses will be based on physician-recorded ICD
codes in administrative data, which are provided for
reimbursement and lumped in 3-month periods.
Inclusion criteria
In order to be able to fill in the data collection tools used
within the process evaluation (e.g. questionnaires), all phy-
sicians, medical assistants, stakeholders and patients, par-
ticipating in the patient survey, should have written and
spoken German language skills and have to be 18 years of
age or older. Additionally, written informed consent is a
prerequisite for participation in the study.
Ambulatory practices and healthcare providers
Ambulatory practices need to be enrolled in one of the
14 participating practice networks in Bavaria and North
Rhine-Westphalia to be eligible for participation. In
addition, physicians need to participate in one of the fol-
lowing medical specialist groups: general practitioner
(Facharzt für Allgemeinmedizin, GP), internists, gynae-
cologist, ENT specialist, urologist, pulmonary specialist
or paediatrician (Additional file 2: Table S1). Out of
these eligible ambulatory practices, physicians specia-
lised in general practice or internal medicine and func-
tioning as GP will be included in the outcome
evaluation. All physicians, who participate in one of the
intervention arms, will be invited to take part in the
process evaluation. Additionally, GPs included in the
outcome evaluation will have the opportunity to
participate in focus group meetings.
Medical assistants employed at one of the eligible and
participating ambulatory practices, which are allocated
to intervention arm B, are eligible for study participation
and will be invited to take part in the process evaluation,
as well.
Patients
Eligible are patients with a diagnosis of an acute non-
complicated infection of the respiratory tract (bronchitis,
sinusitis, tonsillitis, otitis media), acute non-complicated
cystitis or CAP who are insured by AOK health insur-
ance in Bavaria or North Rhine-Westphalia. Eligible pa-
tients of ambulatory practices in intervention arm B,
which are insured by the AOK health insurance in Bavaria,
will be invited to participate in a patient survey.
Exclusion criteria
No additional exclusion criteria for participants are de-
fined. Patients, stakeholders, ambulatory practices and
healthcare providers who do not fulfil the specific inclu-
sion criteria in each part of the study (outcome evalu-
ation, process evaluation and patient survey) will be
excluded.
Study procedures
The primary as well as a few secondary outcomes are
based on pseudonymized claims data (§§ 295, 300 SGB
V). Claims data are based on billing data of physi-
cians––like medical prescriptions, diagnoses (ICD-10
codes) and medical service according to the uniform re-
imbursement scale (‘Einheitlicher Bewertungsmaßstab’)
for medical services. Additionally, routine data of statu-
tory health insurance will be used: (a) hospital and am-
bulatory treatments (as defined by German law §301
SGB V), (b) service of statutory nursing care insurance
(as defined by § 105 SGB IX) and (c) basic claims data
(‘Stammdaten’, as defined by § 284 SGB V).
The process evaluation is based on surveys and inter-
views with healthcare providers and stakeholders. Written
questionnaires will be given to physicians and, in interven-
tion arm B also to medical assistants, three times during
the intervention period. Face-to-face and telephone inter-
views with physicians, medical assistants and stakeholders
will be conducted after the first winter period. The inter-
views will provide additional insight into perceived impact
of intervention components and further explore
contextual factors focusing on impact and structures
of information exchange in practice networks.
Additionally, focus groups will be used to gain feedback
from members of the targeted group at all stages (see
Fig. 2) of the planning, implementation and follow-up of
ARena interventions and to learn from their experiences
and optimise the interventions.
The patient survey will include patients with acute
non-complicated infections in participating practices in
study arm B. Eligible patients will be identified by their
physician (insured by AOK health insurance in Bavaria
and diagnosed with an acute non-complicated infection
of the respiratory tract, non-complicated cystitis or
CAP) and asked to take part in the patient survey by
filling in the anonymous questionnaire.
For a detailed recruitment description of study
participants, see Additional file 2: Table S2.
Financial compensation for study participation
In total, three billing items will be used to reimburse the
patient and study-related extra effort. All participating
physicians will receive 6€ and medical assistants 5€ per
eligible patient and quarter year. Additionally, physicians
in intervention group C using the CDSS will receive 2.81
€ per eligible patient and quarter year.
Physicians, medical assistants and stakeholders who
participate in the interviews within the process
evaluation will receive a reimbursement of 50€ each.
Randomisation procedure
The allocation to the three arms of the study is done by
the study statisticians, using a computer program, and
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concealed from all others in the project. The 14 practice
networks are allocated to one of the three intervention
arms under the constraints that the arms contain a simi-
lar number of practices (not more than one practice
difference) based on an estimated participation rate of
practices within the networks and that intervention arm
A contains 4 practice networks and intervention arms B
and C each 5 practice networks. From a total of 34,650
possible allocation outcomes, 112 meet this requirement,
from which a computer program randomly picks one.
Recommended clinical practice
Recommendations for antibiotic prescribing are derived
from several German high-quality, evidence-based clin-
ical guidelines, most of which were developed by the
German College of General Practitioners and Family
Physicians (DEGAM) [2, 15]. All guidelines used are sys-
tematically developed, evidence- and/or consensus-based
and conform with the quality standards for guidelines in
Germany [16]. In short, they recommend restrained pre-
scription of antibiotics, particularly in healthy patients
with acute non-complicated symptoms. If antibiotics are
used, recommended ones should be preferred instead of
broad-spectrum antibiotics, like quinolones, for example.
Primary and secondary outcome measures
The primary as well as the secondary outcomes of
the claims data based evaluation are defined and op-
erationalized based on previous research in Germany
[17]. Pseudonymized claims data (§§ 295, 300 SGB V)
are used to construct different European Surveillance
of Antimicrobial Consumption Network (ESAC-Net)
indicators [18, 19] measuring the primary and sec-
ondary outcomes.
The primary outcome refers to the following index
indicator, based on different single ESAC-Net indicators:
1. Percentage of patients with acute non-complicated
infections who are treated with antibiotics.
Secondary outcomes refer to the following (ESAC-Net)
indicators:
2. The use of antibiotics in ambulatory care in defined
daily dose (DDD) per 1000 residents (respectively
insured persons) per day and region
3. Percentage of DDD of broad-spectrum quinolones of
all used antibiotics
4. Percentage of DDD of broad-spectrum cephalosporins
(3rd and 4th generation) of all used antibiotics
5. Percentage of patients (18–75 years) with acute
bronchitis, patients (> 18 years) with sinusitis,
patients (> 2 years) with otitis media and patients
(> 1 year) with upper respiratory tract infections/
tonsillitis with a prescription of (a) recommended
antibiotics, if necessary at all, and (b) less
broad-spectrum antibiotics like quinolones
6. Percentage of women (> 18 years) with a diagnosis
of non-complicated cystitis and a prescription of (a)
antibiotics, (b) recommended antibiotics and (c) less
broad-spectrum antibiotics like quinolones
7. Percentage of patients (18–65 years) with
community-acquired pneumonia and a prescription
of (a) antibiotics, (b) recommended antibiotics, (c)
less broad-spectrum antibiotics like quinolones
(> 16 years) and (d) less broad-spectrum antibiotics
like cephalosporins or macrolides (> 16 years)
8. Percentage of patients with acute non-complicated
infections who use medical emergency service
9. Percentage of patients with community-acquired
pneumonia and hospitalisation
The process evaluation will use a mix of measures to
assess the fidelity of the implementation programs, the
potential working mechanisms and the impact of health
system-related factors on outcomes. The impact of par-
ticipation in a practice network on implementation of
new ideas and practices regarding antibiotic prescribing
is of particular interest. Various social mechanisms influ-
ence the spread of new attitudes and behaviours, as well
as the motivation to change the behaviour [10]. In the
exploration, some emphasis will be put on the potential
impact of the networks in which the physicians are em-
bedded. Therefore, tailored questions for interviews and
surveys are phrased, which cover (a) the uptake and per-
ceived impact of intervention components by participants
with a focus on handling patients with acute non-compli-
cated infections, (b) the perceived impact of contextual fac-
tors, particularly those related to practice networks, and (c)
perceptions of patients’ expectations regarding antibiotic
prescribing. The construction of the survey is based on
Ajzen’s [20] theory of planned behaviour. The survey items
are conform with this theoretical framework of Ajzen [20]
and are used to gain specific information about the impact
of (a) each intervention component received, (b) contextual
factors including structural conditions and organisation of
patient care, legal terms and conditions (e.g. legal quality
requirements, reimbursement of patient care by statutory
health insurance) and participation in a practice network,
and (c) perceptions of patients expectation regarding anti-
biotic prescribing on the behaviour of participating physi-
cians and medical assistants. Items are scored on a 5-point
Likert scale ranging from 1 (strongly disagree) to 5
(strongly agree). Interviews will add in-depth understanding
of mechanism of action, particularly those related to prac-
tice networks, and explore uptake and possible adaption to
daily practice of intervention components in more detail.
Both surveys and semi-structured interviews include
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written questions concerning socio-demographic aspects
like age, gender, years of working experience and character-
istics of the working environment.
Focus group interviews will aim to discuss barriers in
implementation of intervention components and to
develop possibilities to overcome these barriers.
Patient survey will be used to gain feedback from patients
concerning their knowledge and views on antibiotics and
antibiotic prescribing, as well as their perception of differ-
ent intervention components targeting patients. Therefore,
a questionnaire will be used covering reason for consult-
ation (complaints/illness), whether antibiotics are expected,
requested and received (yes/no questions), as well as (with
4-point Likert scale) patient education and shared decision
making on antibiotic prescribing, views on delayed anti-
biotic prescription, perceived study components, the role of
non-physician health professionals of the practice team,
general view on antibiotic prescribing in and general satis-
faction with the practice. In addition, age, sex, nationality
and education are recorded. The questionnaire used in the
patient survey is based on published research [21, 22].
Data collection and data management
Outcome evaluation
Primary and secondary outcomes, as well as patient
characteristics, will be extracted from administrative
data at the health insurers involved, so called claims
data. This will be done each quarter year. These data
provide the basis for the outcome evaluation and the
written feedback for participating practices.
Patient characteristics documented from the adminis-
trative data include age, sex, years in insurance, insur-
ance status (principal, family or retired member), patient
participation in disease management programs (diabetes,
breast cancer, asthma, coronary heart disease, COPD,
chronic heart failure) and other additional care pro-
grams. In addition, prescribing physician identification,
medical discipline and physician participation in disease
management programs are recorded.
Process evaluation
Written, paper-based questionnaires will be mailed to
participating physicians in study arms A, B and C, and
in study arm B also to medical assistants. This will be
done three times following their quality circle meetings
by the study central office. Reminders will be sent out
after 2 weeks to increase the response rate. The filled in
questionnaire will be sent to the Department of General
Practice and Health Services Research, University
Hospital Heidelberg. Hence, the survey is pseudonymized,
no identification of the participants’ identity will be
possible.
The questionnaire will be pilot tested with a sample of
four physicians, who are associated with the Department of
General Practice and Health Services Research, University
Hospital Heidelberg and two non-physician health
professionals of the practice team.
Face-to-face and telephone interviews with a sample of
40 physicians and medical assistants as well as an
additional sample of 10 stakeholders will be done by re-
searchers. Each interview will take between 30 to 45 min
and is conducted using a semi-structured interview
guide. The interviews will be audio-recorded, transcribed
verbatim and stored on a secured server of the
University Hospital Heidelberg. Transcripts will be
pseudonymized.
Focus group interviews with one representative of each
practice network will be done every 3 months.
Patient survey
Sixty AOK-insured patients per participating practice
in Bavaria in intervention arm B, who visit the prac-
tice with at least one of the relevant index diseases,
will be invited to complete a written questionnaire
after the consultation. The questionnaire is filled in
anonymously by each patient and is collected in a
sealed box in each practice. A time slot of maximum
3 months is defined for conducting the survey. After-
wards, the sealed box containing the questionnaires is
sent back to the aQua-Institute for data analysis.
A pilot study including telephone interviews with patients
will be conducted in advance to ensure that the questions
are comprehensible from the patients’ point of view.
Data analysis
Outcome evaluation
The primary objective of this study is to examine the
change of the antibiotic prescription rate in targeted pa-
tients within three intervention arms and the comparison
between the three intervention arms. The confirmatory
analysis of the primary endpoint will be conducted on the
basis of the Intention-To-Treat (ITT) population where
all patients will be included in the analysis and assigned to
the group they were randomised to.
To account for multiple testing and to assure a global sig-
nificance level of 5%, a multiple test procedure for hierarch-
ically ordered hypotheses will be applied. In the first stage,
differences regarding the primary endpoint (prescription of
antibiotics) before and after the intervention in intervention
groups B and C are tested. To assure a significance level of
5% within the first level, the hypotheses for the pre- and
post comparison will be tested at a local significance level
of 5/2%. The second step includes the pre-and post com-
parison in intervention group A. The significance level of
the rejected hypotheses from step one is taken (2.5% if only
one hypothesis can be rejected, 5% if both hypotheses can
be rejected). If significance is reached in intervention
groups A and B, differences between groups A and B will
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be tested at a local significance level of 5/2%. Similarly, dif-
ference between groups A and C will be only tested if sig-
nificance is reached for groups A and C in the steps 1 and
2. If the hypotheses in step 1 or 2 cannot be rejected, the
group comparison will not be tested primarily.
In all stages described above, a logistic mixed effects
model will be applied to assess the respective hypotheses
regarding the primary endpoint. In the first and second
stage, the time (before/after the intervention) is included
as fixed effect. A random intercept will be included for
patients and for practices. For the comparisons in the
third stage, the intervention group will be included as
fixed effect additionally. Furthermore, age and gender
will be included as covariates. Finally, sensitivity analyses
will be conducted using different populations (per protocol
population where patients with major protocol violations
are excluded and appropriate subgroups). Since all these
analyses are based on claims data, missing values cannot be
tracked.
Descriptive methods will be used for the analysis of
the secondary outcomes, including the calculation of ap-
propriate summary measures of the empirical distribu-
tion (mean, standard deviation, median, IQR, minimum
and maximum for continuous variables and frequency in
percentages for categorical variables). In addition, similar
mixed models as described for the primary endpoint will
be used. All calculated p values regarding secondary
outcomes will have descriptive character only.
Furthermore, differences between the intervention groups
and an untreated comparison group will be tested. The
comparison group consists of claims data of patients in-
sured by AOK health insurance in non-participating prac-
tices in Bavaria and North Rhine-Westphalia. Therefore,
propensity score matching will be used to generate 14
virtual clusters of non-participating practices.
A detailed statistical analysis plan is written prior to
the final analysis. SAS (SAS Institute Inc., Cary, NC,
USA), version 9.4 or higher, is used to carry out the
analyses.
Process evaluation
Descriptive statistics will be used to characterise the study
sample and to analyse the survey data of physicians and
medical assistants according to intervention fidelity, e.g.
adherence to different intervention components. More-
over, regression analysis will be used to gain information
about the dependence between claims data based outcome
measures and (a) the uptake and perceived impact of
intervention components by participants, (b) the
perceived impact of contextual factors, particularly those
related to the practice networks, (c) perceptions of
patients’ expectations regarding antibiotic prescribing.
The semi-structured interviews will be audio-taped
and transcribed verbatim. The interview data will be
qualitatively analysed using thematic framework analysis
to classify and organise data according to key themes,
concepts and predefined categories. The transcripts will
be analysed and coded by researchers using qualitative
data analysis software (e.g. Atlas.ti). Predefined categor-
ies of the framework of Flottorp et al. [23] will be used
to identify determinants of practice regarding improve-
ments in health professional practice concerning the
appropriate use of antibiotics in acute non-complicated
infections in ambulatory care.
Aims of the focus group discussions are (a) to under-
stand opinions of the targeted groups of study partici-
pants, (b) to identify barriers in the implementation
process and (c) to reflect consequences for a possible
further development of the intervention. The duration of
discussion per topic during the meetings will serve as
parameter to identify key topics, main barriers and dis-
cussed solutions to overcome possible difficulties. Basis
of this analysis will be structured manuals and
audiotapes of each meeting.
Data triangulation will occur through an integrated ap-
proach where qualitative and quantitative data will be
systematically incorporated. This will be done after all
sets of data have already been analysed individually. This
approach strengthens the analysis by taking a more
holistic approach to analysing data and evaluating the
study [24].
Patient survey
Descriptive statistics will be used to analyse the data col-
lected through the patient survey. This will be done (a)
in order to characterise the patient sample, (b) to show
the frequencies of answers given to the questions (e.g.
antibiotics expected vs. antibiotics received, information
on antibiotics received, item response). Additionally, cor-
relation and regression analysis will be done with data
collected in the main surveys, e.g. in order to detect de-
pendences between patients’ characteristics (age, sex,
etc.) or their actual (index)-disease and patients’ experi-
ences and expectations concerning antibiotic prescribing.
Sample size calculation
The sample size calculation is based on the expectation
to find an absolute reduction of the antibiotic prescrip-
tion rate in targeted patients from 61 to 50% in interven-
tion group A and from 61 to 45% in groups B and C.
Thus, the effect is expected to be 5% higher in the
enriched intervention groups B and C compared to
intervention group A.
To control the overall type I error rate at 0.05
(two-sided), a hierarchical 3-step testing procedure will
be applied. In the first step, the hypotheses of no differ-
ence between the pre- and post prescription rate in group
B and C will be tested. If at least one of these hypotheses
Kamradt et al. Implementation Science  (2018) 13:23 Page 8 of 10
can be rejected, the hypothesis of no difference in the pre-
and post rate in group A will be tested. If, additionally, this
hypothesis can be rejected, the hypotheses of no difference
between the post rates of groups A and B as well as
groups B and C will be tested. The sample size is calcu-
lated based on chi-squared tests assuring a (global) power
of 80% for the rejection of all the above described, hier-
archically ordered hypotheses. Furthermore, to take the
clustered structure into account, an intra-cluster correlation
coefficient (ICC) for patients in practices of 0.05 and of 0.7
for cases clustered in patients is assumed. Together with
the above described expected pre- and post prescription
rates in the three groups, this results in a sample size of
23,933 patients in group A, 11,967 patients in group B and
11,967 patients in group C. With an average practice
size of 80 patients per quarter this leads to 75 prac-
tices in group A, 38 practices in group B and 38
practices in group C.
Discussion
The evidence base of large scale programs to reduce anti-
biotic prescribing in acute non-complicated infections in
primary care is limited, so this project can provide an im-
portant contribution. Nevertheless, a number of limita-
tions of the study should be acknowledged. The study is
randomised, but the number of units for allocation (i.e.
networks) is small, leaving room for bias. Primary and sec-
ondary outcomes are based on claims data, which have in-
herent limitations and strengths. Given the multifaceted
programs, it will be difficult to separate out the impact of
various program components. On the other hand, strong
aspects of the program are its large scale and closeness to
daily practice. The focus on practice networks and imple-
mentation outcomes, which will be explored in the
process evaluation, adds value to the study. The analysis
of components of the complex implementation programs,
using the TIDier checklist, contributes to the transparency
of the implementation programs.
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